Abstract:Development of resistance to cisplatin, oxaliplatin and carboplatin remains a challenge for their use as chemotherapies, particularly in breast and colorectal cancer. Here, we compare the anticancer effect of novel complexes [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtIIPHENSS), [Pt(5-methyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtII5MESS) and [Pt(5,6-dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)](NO3)2 (PtII56MESS) and their platinum(IV)-dihydroxy derivatives with cisplatin. Complexes are greater than 11-fold more potent than cisplatin in both 2D and 3D cell line cultures with increased selectivity for cancer cells over genetically stable cells. ICP-MS studies showed cellular uptake occurred through an active transport mechanism with considerably altered platinum concentrations found in the cytoskeleton across all complexes after 24 h. Significant reactive oxygen species generation was observed, with reduced mitochondrial membrane potential at 72 h of treatment. Late apoptosis/necrosis was shown by Annexin V-FITC/PI flow cytometry assay, accompanied by increased sub-G0/G1 cells compared with untreated cells. An increase in S and G2+M cells was seen with all complexes. Treatment resulted in significant changes in actin and tubulin staining. Intrinsic and extrinsic apoptosis markers, MAPK/ERK and PI3K/AKT activation markers, together with autophagy markers showed significant activation of these pathways by Western blot. The proteomic profile investigated post-72 h of treatment identified 1597 MDA-MB-231 and 1859 HT29 proteins quantified by mass spectroscopy, with several differentially expressed proteins relative to no treatment. GO enrichment analysis revealed a statistically significant enrichment of RNA/DNA-associated proteins in both the cell lines and specific additional processes for individual drugs. This study shows that these novel agents function as multi-mechanistic chemotherapeutics, offering promising anticancer potential, and thereby supporting further research into their application as cancer therapeutics.

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity

Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity

Anticancer Effect of PtIIPHEN SS, PtII5ME SS, PtII56ME SS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

Synthesis and Biological Activity of Binuclear Platinum Complexes Containing Two Monofunctional Cis-[Pt(Nh3)(2)Cl](+) Units Bridged by 4,4 '-Dipyridyl Selenides or Sulfides

Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs

Synthesis and Anticancer Activity of [2-Hydroxy-1,3-diaminopropane-κ2n,n′] Platinum(ii) Complexes

Pt( iv ) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Novel Platinum(iv) Complexes Conjugated with a Wogonin Derivative As Multi-Targeted Anticancer Agents.

A Dual Action Platinum(IV) Complex with Self‐assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway

Antitumor Platinum(II) Complexes with 1,10-phenanthroline and Hydrophilic Alkoxyacetates as Ligands.

Ptxplatin: An multifunctional Pt(IV) antitumor prodrug

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin

Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester As a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Reversal of Cisplatin Resistance in Human Gastric Cancer Cells by a Wogonin-Conjugated Pt(IV) Prodrug Via Attenuating Casein Kinase 2-Mediated Nuclear Factor-κB Pathways.